4
Changes in Ownership
Mineralys Therapeutics, Inc. Filed Acc 0001816952-26-000005
Director sold 3,000 shares at $28.58 ($85,740)
- Director acquired 3,000 shares (option exercise)
- Traded under a Rule 10b5-1 plan
From the SEC's structured data for this filing
Trades in this filing
Karydas Daphne · Director
Table I: Non-derivative
2 lines| Date | Transaction | Shares | Price | Value | Owned after | D/I |
|---|---|---|---|---|---|---|
| 2026-09-15 | Exercise or conversion : show line 1 in the form 10b5-1 | +3,000 | $12.02 | $36,060 | 9,200 | D |
| 2026-09-15 | Sale : show line 2 in the form 10b5-1 | −3,000 | $28.58 | $85,740 | 6,200 | D |
| Open-market sales · 3,000 sh · avg $28.58 · $85,740 | ||||||
Table II: Derivative
1 line| Date | Transaction | Shares | Owned after | D/I |
|---|---|---|---|---|
| 2026-09-15 | Exercise or conversion : show line 3 in the form 10b5-1 Stock Option | −3,000 | 35,000 | D |
Loading xslF345X06/wk-form4_1789681270.xml…